• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

靶向蛋白降解技术在 G 蛋白偶联受体中的应用。

The application of targeted protein degradation technologies to G protein-coupled receptors.

机构信息

Drug Discovery Biology Theme, Monash Institute of Pharmaceutical Sciences, Monash University, 399 Royal Parade, Parkville, 3052, Victoria, Australia.

Medicinal Chemistry Theme, Monash Institute of Pharmaceutical Sciences, Monash University, 399 Royal Parade, Parkville, 3052, Victoria, Australia.

出版信息

Br J Pharmacol. 2024 Jul;181(14):2351-2358. doi: 10.1111/bph.16079. Epub 2023 Apr 20.

DOI:10.1111/bph.16079
PMID:36965004
Abstract

The ubiquitin-proteasome system is one of the major pathways for the degradation of cellular proteins. In recent years, methods have been developed to exploit the ubiquitin-proteasome system to artificially degrade target proteins. Targeted protein degraders are extremely useful as biological tools for discovery research. They have also been developed as novel therapeutics with several targeted protein degraders currently in clinical trials. However, almost all targeted protein degrader technologies have been developed for cytosolic proteins. The G protein-coupled receptor (GPCR) superfamily is one of the most important classes of drug targets, yet only limited examples of GPCR degradation exist. Here, we review these examples and provide a perspective on the different strategies that have been used to apply targeted protein degradation to GPCRs. We also discuss whether alternative approaches that have been used to degrade other integral membrane proteins could be applied to the degradation of GPCRs. LINKED ARTICLES: This article is part of a themed issue Therapeutic Targeting of G Protein-Coupled Receptors: hot topics from the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists 2021 Virtual Annual Scientific Meeting. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v181.14/issuetoc.

摘要

泛素-蛋白酶体系统是细胞内蛋白质降解的主要途径之一。近年来,已经开发出利用泛素-蛋白酶体系统人为降解靶蛋白的方法。靶向蛋白降解剂作为发现研究的生物工具非常有用。它们也已被开发为新型治疗药物,目前有几种靶向蛋白降解剂正在临床试验中。然而,几乎所有的靶向蛋白降解技术都是针对细胞质蛋白开发的。G 蛋白偶联受体(GPCR)超家族是最重要的药物靶点之一,但仅存在有限的 GPCR 降解的例子。在这里,我们回顾了这些例子,并对应用靶向蛋白降解技术于 GPCR 的不同策略提供了一个视角。我们还讨论了是否可以将已用于降解其他整合膜蛋白的替代方法应用于 GPCR 的降解。

相关文章

本文是治疗性靶向 G 蛋白偶联受体:2021 年澳大拉西亚临床和实验药理学和毒理学学会虚拟年会热点话题特刊的一部分。要查看本节中的其他文章,请访问 http://onlinelibrary.wiley.com/doi/10.1111/bph.v181.14/issuetoc.

相似文献

1
The application of targeted protein degradation technologies to G protein-coupled receptors.靶向蛋白降解技术在 G 蛋白偶联受体中的应用。
Br J Pharmacol. 2024 Jul;181(14):2351-2358. doi: 10.1111/bph.16079. Epub 2023 Apr 20.
2
Highlights and hot topics in GPCR research from 'Down Under'.来自“澳大利亚”的 GPCR 研究的亮点和热门话题。
Br J Pharmacol. 2024 Jul;181(14):2091-2094. doi: 10.1111/bph.16419. Epub 2024 May 26.
3
The application of artificial intelligence to accelerate G protein-coupled receptor drug discovery.人工智能在 G 蛋白偶联受体药物发现中的应用。
Br J Pharmacol. 2024 Jul;181(14):2371-2384. doi: 10.1111/bph.16140. Epub 2023 May 26.
4
Molecular insights into orphan G protein-coupled receptors relevant to schizophrenia.与精神分裂症相关的孤儿 G 蛋白偶联受体的分子见解。
Br J Pharmacol. 2024 Jul;181(14):2095-2113. doi: 10.1111/bph.16221. Epub 2023 Sep 26.
5
Unravelling G protein-coupled receptor signalling networks using global phosphoproteomics.运用全局磷酸化蛋白质组学揭示 G 蛋白偶联受体信号转导网络。
Br J Pharmacol. 2024 Jul;181(14):2359-2370. doi: 10.1111/bph.16052. Epub 2023 Feb 24.
6
Targeting G protein-coupled receptors for heart failure treatment.针对心力衰竭治疗的 G 蛋白偶联受体。
Br J Pharmacol. 2024 Jul;181(14):2270-2286. doi: 10.1111/bph.16099. Epub 2023 Jun 16.
7
The roles of RGS proteins in cardiometabolic disease.RGS蛋白在心脏代谢疾病中的作用。
Br J Pharmacol. 2024 Jul;181(14):2319-2337. doi: 10.1111/bph.16076. Epub 2023 Apr 19.
8
Therapeutic potential of allosteric modulators for the treatment of gastrointestinal motility disorders.变构调节剂治疗胃肠动力障碍的治疗潜力。
Br J Pharmacol. 2024 Jul;181(14):2232-2246. doi: 10.1111/bph.16023. Epub 2023 Jan 18.
9
Single nucleotide variations encoding missense mutations in G protein-coupled receptors may contribute to autism.编码 G 蛋白偶联受体错义突变的单核苷酸变异可能与自闭症有关。
Br J Pharmacol. 2024 Jul;181(14):2158-2181. doi: 10.1111/bph.16057. Epub 2023 Mar 12.
10
Molecular pharmacology of G protein-coupled receptors.G蛋白偶联受体的分子药理学
Br J Pharmacol. 2016 Oct;173(20):2931-3. doi: 10.1111/bph.13610.

引用本文的文献

1
How to target membrane proteins for degradation: Bringing GPCRs into the TPD fold.如何靶向降解膜蛋白:将G蛋白偶联受体纳入靶向蛋白质降解框架
J Biol Chem. 2024 Dec;300(12):107926. doi: 10.1016/j.jbc.2024.107926. Epub 2024 Oct 23.
2
Inducing Receptor Degradation as a Novel Approach to Target CC Chemokine Receptor 2 (CCR2).诱导受体降解作为靶向 C 型趋化因子受体 2(CCR2)的新方法。
Int J Mol Sci. 2024 Aug 18;25(16):8984. doi: 10.3390/ijms25168984.
3
PROTACs: Emerging Targeted Protein Degradation Approaches for Advanced Druggable Strategies.
PROTACs:用于先进成药性策略的新兴靶向蛋白降解方法。
Molecules. 2023 May 10;28(10):4014. doi: 10.3390/molecules28104014.